PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11464473

[Recent progress in treatment for multiple sclerosis].

J Kira
View original source ↗Export metadata ↓

Abstract

Multiple sclerosis (MS) is currently considered to be an autoimmune disease mediated by myelin antigen-specific Th 1 cells. Although the mechanism of MS remains to be elucidated, new disease modifying drugs have recently been introduced to MS treatment. Interferon-beta, copolymer 1 and intravenous administration of immunoglobulins have been shown to significantly reduce the relapse rate, progression of disease and increase of MRI lesion load in MS. However, as the effects of these drugs are nonspecific immunomodulation, specific immunomodulation therapy for MS is called for. T cell vaccination, altered peptide ligand and oral tolerance are possible candidates for specific immune therapy for MS. As in Asians there is such a distinct subtype of MS as HLA-DPB 1 * 0501-associated opticospinal MS, it is important to look for unique immune therapy for opticospinal MS in future.

Explore related subjects

Glatiramer AcetateHumansImmunoglobulins, IntravenousImmunotherapyInterferon-betaLymphocyte ActivationMultiple SclerosisPeptidesT-LymphocytesVaccinesEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Kira. 2000. [Recent progress in treatment for multiple sclerosis].. https://pubmed.ncbi.nlm.nih.gov/11464473/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Glatiramer acetate therapy for multiple sclerosis: a review.

The past decade has witnessed a revolution in the treatment of multiple sclerosis (MS), the most common demyelinating disorder of the human CNS. After being considered as an untreatable disease for more than a century, six disease-modifying treatments have been approved between 1993 and 2006. Glatiramer acetate (GA) is a worldwide drug approved for the treatment of relapsing-remitting MS in 1996. The drug is a synthetic copolymer of four amino acids based on the composition of myelin basic protein, one of several putative autoantigens implicated in the pathogenesis of MS. Three separate double-blind, placebo-controlled trials have established its efficacy in relapsing-remitting MS. Observations from an ongoing study, the longest prospective study in MS therapeutics so far, suggest that the effect of GA in reducing the relapse rate and neurological disability is maintained over a 10-year period. Independent investigators have identified several putative immunological mechanisms of action of GA, with the unique observation of the generation of GA-reactive T-helper 2 (anti-inflammatory) polarised lymphocytes within days to weeks of initiating therapy and sustaining an anti-inflammatory milieu for years in the peripheral immune system and, presumably, in the CNS. Emerging data from immunological and imaging studies quantifying axonal injury in the brain point towards neuroprotective abilities of GA. Combined with its remarkable safety and tolerability, long-term efficacy and neuroprotective effect, GA presents it self as a first-line choice in relapsing-remitting MS, and holds immense promise in developing its potential as a combination therapy in MS, as well as extending its indications to other neurodegenerative diseases.

Glatiramer Acetate↗
PubMed2005

A practical approach to immunomodulatory therapy for multiple sclerosis.

This article provides a current overview of the definition and pathogenesis of the disease, the different types of MS, a new diagnostic criteria, the rationale for early therapy, a review of the approved MS therapies, the strategies to evaluate ongoing treatment efficacy,the management of suboptimal treatment responders, and the prospects for future therapies. The article focuses on relapsing remitting MS because most of the therapeutic data deal with this type of MS. The role of mitoxantrone as a "rescue therapy" for suboptimal responders to IMTs is discussed.

Glatiramer Acetate↗